Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Utah Medical ProductsUTMD +0.41%73 Return-on-Tangible-Asset is 9.75% as of Jun. 2026, which is 43% below its 10-year median of 17.04. GuruFocus rates UTMD with a GF Score™ of 73/100 and a GF Value™ of $57.89 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Utah Medical Products ranks better than 79.95% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Utah Medical Products's annualizedNet Income for the quarter that ended in Jun. 2026 was $10.74 Mil. Utah Medical Products's average total tangible assets for the quarter that ended in Jun. 2026 was $110.18 Mil. Therefore, Utah Medical Products's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 9.75%.
The historical rank and industry rank for Utah Medical Products's Return-on-Tangible-Asset or its related term are showing as below:
UTMD'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 9.72 Med: 17.04 Max: 28.64
Current: 9.72
During the past 13 years, Utah Medical Products's highest Return-on-Tangible-Asset was 28.64%. The lowest was 9.72%. And the median was 17.04%.
UTMD's Return-on-Tangible-Asset is ranked better than 79.95% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.89
vs UTMD: 9.72
Utah Medical Products (NAS:UTMD) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Utah Medical Products Return-on-Tangible-Asset Related Terms
Utah Medical Products Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Utah Medical Products's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Utah Medical Products Return-on-Tangible-Asset Chart
UTMD vs EMBC, SMTI, PDEX: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Utah Medical Products's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Utah Medical Products Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Utah Medical Products's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Utah Medical Products's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 9.75% mean?
Utah Medical Products (UTMD) has a Return-on-Tangible-Asset of 9.75% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Utah Medical Products and its competitors. This is 43% below median its historical median of 17.04. Over the past decade, Utah Medical Products' Return-on-Tangible-Asset has ranged from 9.72 to 28.64. According to the industry distribution chart, Utah Medical Products ranks #171 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 20%.
Is Utah Medical Products' Return-on-Tangible-Asset too high?
Utah Medical Products' current Return-on-Tangible-Asset of 9.75% is 43% below median its 10-year median of 17.04. Over the past 10 years, this metric has ranged from a low of 9.72 to a high of 28.64. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. Utah Medical Products' value of 9.75% is 995.5% above this industry median. Based on the distribution chart, Utah Medical Products ranks #171 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Utah Medical Products has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Utah Medical Products' Return-on-Tangible-Asset compare to EMBC and SMTI?
According to the Medical Devices & Instruments industry distribution chart, Utah Medical Products ranks #171 out of 853 companies for Return-on-Tangible-Asset. This places Utah Medical Products in the top 20% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.89. Utah Medical Products' value of 9.75% is 995.5% above this benchmark. Historically, Utah Medical Products' own Return-on-Tangible-Asset has ranged from 9.72 to 28.64 over the past decade. While the company's 10-year median is 17.04 vs. the industry median of 0.89, Utah Medical Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Utah Medical Products's current Return-on-Tangible-Asset of 9.75% is 995.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Utah Medical Products and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Utah Medical Products's current Return-on-Tangible-Asset is 9.75%, which is 43% below median its own 10-year median of 17.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Utah Medical Products stock overvalued right now?
Based on GuruFocus' analysis, Utah Medical Products (UTMD) is currently considered Modestly Overvalued. The stock's GF Value™ is $57.89, compared to a current price of $70.84 — trading 22.4% above its estimated fair value. The current Return-on-Tangible-Asset is 9.75%, which is 43% below median its 10-year median of 17.04 and 995.5% above the Medical Devices & Instruments industry median of 0.89. Utah Medical Products' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Utah Medical Products (UTMD), the current Return-on-Tangible-Asset is 9.75% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Utah Medical Products (UTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Utah Medical Products stock appears to be overvalued.
The current stock price of $70.84 is trading 22.4% above its estimated GF Value™ of $57.89.
GuruFocus considers Utah Medical Products to be Modestly Overvalued.
Key valuation signals for UTMD:
Return-on-Tangible-Asset: 9.75% (43% below median its 10-year median of 17.04)
GF Value™: $57.89 vs. price of $70.84 (22.4% above fair value)
Industry Position: 995.5% above the Medical Devices & Instruments median (#171 of 853)
No single metric tells the full story. See the UTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, and Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals, and outpatient clinics and physicians' offices.
73GF Score
Get the complete analysis for UTMD
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UTMD has been successfully added to your 
